Medicilon Supports Moon Biotech’s Groundbreaking MNO-863 Probiotic Drug – Achieves Nearly 10% Weight Loss in 4 Weeks and Secures Dual Clinical Trial Trial Approvals
2025-04-18 Moon Biotech recently has announced that its innovative probiotic drug, MNO-863 enteric-coated capsules, has been approved for clinical trials by China’s NMPA. This follows earlier approval from the U.S. FDA, marking a rare dual greenlight across both major regulatory bodies. Medicilon is proud to have been a trusted R&D partner in this achievement, […]
Zero Defects! Medicilon Supports MeiJi BioPharma’s Oral Paclitaxel Soft Capsule in Gaining FDA IND Approval
2025-04-11 Meiji BioPharma has received FDA approval for its IND application for an oral paclitaxel soft capsule with “zero defects.” This marks the world’s first and only oral paclitaxel soft capsule project to receive clinical trial approval. Medicilon as a long-term partner of Meiji BioPharma, provided comprehensive preclinical R&D services, including formulation development, pharmacodynamics, […]
Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance
On February 26, Tyercan announced that its independently developed first-in-class drug, Tye1001, received clinical trial approval from China’s NMPA, following its approval by the US FDA on July 12, 2024. This marks a significant milestone of dual approval in both China and the US. As Tyercan’s partner, Medicilon delivered comprehensive GLP-compliant preclinical services, including pharmacodynamics, […]
